

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 33/42, 33/10		(11) International Publication Number: WO 95/10290
A1		(43) International Publication Date: 20 April 1995 (20.04.95)
(21) International Application Number: PCT/US94/11548		(81) Designated States: AU, CA, JP, NZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(22) International Filing Date: 11 October 1994 (11.10.94)		
(30) Priority Data: 08/136,570 <u>13 October 1993 (13.10.93)</u> US 08/316,416 <u>5 October 1994 (05.10.94)</u> US		Published <i>With international search report.</i>
(71) Applicant: WARNER-LAMBERT COMPANY (US/US); 201 Tabor Road, Morris Plains, NJ 07950 (US).		
(72) Inventors: GEORGIADIS, Constantine; 6 Huron Court, East Brunswick, NJ 08816 (US). BUCH, R., Michael; 519 Faulkner Drive, Hackensack, NJ 07840 (US). ENGELMAN, E., Eric; 688 Penn Estates, East Stroudsburg, PA 18301 (US). VOLPE, Frank, A.; 14 Powderhorn Drive, Kinnelon, NJ 07405 (US).		
(74) Agents: BARISH, Jean; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.		
(54) Title: ANTACID PHARMACEUTICAL COMPOSITION		
(57) Abstract <p>Antacid pharmaceutical compositions provide optimal buffering profiles of from 3.0 to 5.0 for immediate and long-lasting relief from the symptoms of acid indigestion, sour stomach, heartburn and gas. The composition may comprise a dual or tripartite combination of the actives calcium carbonate, calcium or magnesium citrate and/or calcium phosphate which, as a result of their different activities, neutralize the excess stomach acid both immediately and continuously over time. The formulations also provide the individual with alternative dosage forms which may provide greater levels of calcium, less sodium and less <u>production</u> of gastrointestinal gas.</p>		

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LR	Sierra Leone	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Antacid Pharmaceutical CompositionBackground of the Invention

5 The present invention relates generally to pharmaceutical compositions comprising active agents useful in the treatment of upper gastrointestinal disorders such as what is commonly referred to as sour stomach, upset stomach, heartburn, gas, acid indigestion and the like. Pharmaceutical compositions containing antacid agents useful for treating gastrointestinal problems are widely used and have been around for quite some time. They vary to some extent in the active ingredients and other excipients and increasingly vary with respect to the other ingredients used that are responsible for flavor, texture, mouthfeel and mechanisms of delivery.

15 Ingestible pharmaceutical agents capable of relieving gastrointestinal distress typically work by neutralizing stomach acid. Predominantly, these antacids comprise a carbonate or hydroxide of an alkaline earth metal salt such as calcium carbonate or magnesium hydroxide. In terms of simple chemistry, using calcium carbonate as an example, the neutralization reaction occurs as follows



25 These agents unfortunately also present a chalky, gritty mouthfeel which must somehow be taste-masked in order to insure good patient compliance. Whereas certain levels of the active agent are needed in order to achieve the optimal buffering profile of pH 3.0-5.0, large amounts of the metal salt in the tablet or liquid dosage form can substantially detract from its palatability. A happy medium is required then, that provides both quick, upfront and sustained relief while at the same time is incorporated in the delivery system at levels that do not render the medication bad tasting.

30 United States Patent No. 3,621,094 to Mayrom et. al. discloses an aqueous pharmaceutical composition for the treatment of acid indigestion and ulcers comprising a high concentration of antacid and a combination of monobasic calcium phosphate and a non-toxic alkali metal or alkaline gluconate salt such as sodium, potassium, calcium and the like. It is

asserted that the use of monobasic calcium phosphate and the gluconate salt permits the incorporation of higher levels of antacid than previously possible. These high levels of antacid are particularly necessary in the treatment of peptic ulcers. It is asserted that the composition is effective in reducing gastrointestinal discomfort while at the same time affording the patient a palatable tablet form.

United States Patent No. 4,766,502 to Chapura et. al. discloses palatable pharmaceutical compositions useful in the treatment of gastrointestinal disorders comprising a bismuth or metallic antacid salt such as calcium carbonate or aluminum phosphate, a lipid material with a melting point of from about 26°C to about 37°C, a hydrophilic dispersant such as a sugar alcohol and an emulsifier. The compositions allegedly allow for the incorporation of sufficiently high amounts of the active for quick and long lasting relief while at the same time providing for a good tasting, smooth textured means of delivery.

United States Patent 3,573,006 to Shik et. al. discloses an antacid composition comprising a polymeric aluminum and magnesium hydroxy complex in a pharmaceutically acceptable carrier for the relief of stomach acid distress, and is allegedly pleasant tasting with a non-gritty mouthfeel.

United States Patent No. 4,495,087 to Wright et. al. teaches a palatable antacid consisting of an aluminum hydroxycarbonate gel that is effective in buffering high levels of stomach acid.

Finally, U.S. Patent No. 4,592,039 to Duvall et. al. discloses an effervescent analgesic antacid with reduced sodium content for those who must restrict their sodium intake. Aspirin, acetaminophen, ibuprofen and the like are combined with an antacid selected from the group consisting of citric acid, sodium bicarbonate, calcium carbonate, potassium bicarbonate and other fillers, flavors and sweeteners.

It is relatively clear then that there have been many formulations in the past developed to reduce gastrointestinal distress that utilize metal salts such as calcium carbonate, dihydroxy aluminum sodium carbonate (DASC), calcium phosphate, sodium citrate, magnesium carbonate, monobasic calcium phosphate aluminum carbonate, aluminum hydroxide and the like. Few of

these however, have been able to provide an antacid that is both fast acting for immediate upfront relief, long lasting for sustained relief and yet good tasting with a palatable mouthfeel. Whereas DASC formulations are able to achieve optimal buffering, few have provided an optimal buffering profile of from about 3.0 to about 5.0 pH both quickly and for long periods of time, yet also taste good when administered. And whereas on the one hand they provide relief by neutralizing the stomach acid, the subsequent evolution of CO₂ gas can unfortunately result in another form of discomfort for many.

Summary of the Invention

The present invention is a pharmaceutical composition comprising an antacid that provides both immediate, intermediate, and long lasting relief while being low in sodium, aluminum-free and yet possessing a good taste and mouthfeel when administered. The composition contains calcium carbonate in combination with another buffer such as calcium or magnesium citrate, and/or calcium phosphate and mixtures thereof and thereby may also provide a dietary supplement of calcium while offsetting the prevention of phosphate absorption by providing additional phosphate. In a preferred embodiment, a tripartite formulation of calcium carbonate, calcium citrate and calcium phosphate provides both up-front, immediate acid neutralization that is also a sustained long lasting relief without over-compensating to highly basic pH levels. Low in sodium and aluminum-free, these formulations provide not only a source of calcium but generate little gas by utilizing other non-carbonate buffers. The antacid formulation provides optimal acid neutralizing capability and may also comprise other standard antacid filler and flavor ingredients as desired to prepare either a liquid or solid dosage form.

Brief Description of the Drawings

Figure 1 is a graph depicting the continuous acid challenge profile of calcium carbonate/calcium citrate formulations of the present invention as a function of pH versus time.

Figure 2 is a graph depicting the continuous acid challenge profile of calcium carbonate/calcium phosphate formulations of the present invention as a function of pH versus time.

5 Figure 3 is a graph depicting the continuous acid challenge profile of calcium carbonate/calcium citrate/tri-calcium phosphate formulations of the present invention as a function of pH versus time.

Figure 4 is a graph depicting the continuous acid challenge profile of calcium carbonate/calcium phosphate/magnesium citrate formulations of the present invention as a function of pH versus time.

10 Detailed Description of the Invention

Antacids and other similar gastrointestinal medications relieve symptoms such as the burning, painful sensation of heartburn and indigestion through neutralization of acid formed in the stomach. Few antacids are available however, that afford both immediate, upfront relief
15 and sustained, long lasting relief over time. It is well known that the ideally neutralized stomach environment is at a pH of from about 3.0 to about 5.0, and it is when acid buildup lowers the pH below 3.0 that mucosal erosion, the pain of heartburn, acid indigestion and associated discomfort sets in. Obviously then, a rapid correction and maintenance of the stomach pH in this
20 optimal realm will alleviate most discomfort.

The formulations of the present invention are based upon the theory that the buffering profile of a mix of ingredients with different solubilities will provide acid neutralization action at different times and hence will result in overlapping pH profiles. The ability of a medication to relieve the
25 symptoms associated with heartburn, sour stomach, and acid indigestion is measured in terms of its acid neutralizing capacity (ANC) and is a function of its ability to maintain the stomach at conditions with pH values of from about 3.0 to about 5.0 over time. The formulations of the present invention were discovered to surprisingly and unexpectedly neutralize strongly acidic
30 conditions to this range immediately upon consumption and for extended periods of time. For example, calcium carbonate (CaCO_3) provides substantially long lasting, sustained action relief. Its onset is more delayed

and slower than that of the other more soluble components. Calcium citrate provides substantially greater up-front and immediate release so that the two, when combined together provide a broader spectrum of acid neutralizing therapy.

5 The acid neutralizing capacity for each buffer varies and hence the amount of buffer incorporated in an antacid dosage form is dependent upon the relative ANC's for each component. As used herein, the amount of buffer used in the claimed formulations will be defined in terms of its ANC and the amount contributed by a component as a percentage of the total.

10 Calcium carbonate has an acid neutralizing capacity of 20 per gram; that is, one (1) gram of calcium carbonate will neutralize 20 (mls.) of 1N acid or 20 meq. thereof. Calcium citrate has an ANC of 6.5 so that 1.0 gram of calcium citrate will neutralize 6.5 mls. 1N acid or 6.5 meq. thereof. Magnesium citrate has an ANC of 3.5 so that 1.0 gram of magnesium citrate
15 will neutralize 3.5 mls. 1N acid or 3.5 meq. thereof. In one embodiment of the present invention where only a two-component formulation is contemplated, calcium carbonate is incorporated in an amount that will contribute from about 20% to about 80% of the total ANC while the calcium citrate portion is incorporated in the tablet in an amount that will contribute
20 from about 80% to about 20% of the total ANC. Preferably, the two will be incorporated in amounts that will each contribute 50% of the total ANC of the dose form.

 One preferred embodiment of the present invention is a tripartite system in which calcium carbonate, calcium citrate and calcium phosphate,
25 either di- or tri-basic, are combined in ratios which will achieve the optimal buffering levels both immediately and for sustained periods of time. As before, the amounts of each will comprise a percentage of the total that effectively contributes to the overall ANC of the formulation. The exact amounts in terms of weight percentage will vary depending upon the size of
30 the tablet formulated. The weight amount, however can easily be calculated by one skilled in the art knowing the ratios and the respective ANC's of each component. Preferably, calcium carbonate will be incorporated in an amount that will contribute from about 20% to about 70% of the total ANC. Calcium citrate will be incorporated in an amount that will contribute from about 20%

to about 35% of the total ANC of the system while the calcium phosphate, di- or tri-basic, is incorporated in an amount that will contribute from about 20% to 50% of the total ANC of the antacid composition. More preferably, each component will be incorporated in an amount that will contribute from about 30% to about 40% of the total ANC while most preferably each component will be incorporated in an amount that will contribute about one-third of the total ANC of the formulation.

Another preferred embodiment of the present invention is a tripartite system in which calcium carbonate, calcium phosphate, either di- or tri-basic, and magnesium citrate are combined in ratios which will achieve the optimal buffering levels both immediately and for sustained periods of time. As before, the amounts of each will comprise a percentage of the total that effectively contributes to the overall ANC of the formulation. The exact amounts in terms of weight percentage will vary depending upon the size of the tablet formulated. The weight amount, however can easily be calculated by one skilled in the art knowing the ratios and the respective ANC's of each component. Preferably, calcium carbonate will be incorporated in an amount that will contribute from about 20% to about 80% of the total ANC. Magnesium citrate will be incorporated in an amount that will contribute from about 5% to about 30% of the total ANC of the system while the calcium phosphate, di- or tri-basic, is incorporated in an amount that will contribute from about 15% to 50% of the total ANC of the antacid composition. More preferably, magnesium citrate will be incorporated in an amount that will contribute about 8% to about 15% of the total ANC, while the remainder of the ANC will be contributed by calcium carbonate and calcium phosphate, di- or tri-basic.

These formulations then surprisingly and unexpectedly are able to achieve the optimal buffering profile as achieved by dihydroxy aluminum sodium carbonate (DASC) while at the same time providing a source of calcium that is sodium and aluminum free. And despite the presence of this calcium in the system, the additional phosphate that is made available through the calcium phosphate offsets the prevention of phosphate absorption otherwise caused by the calcium. Moreover, the tripartite system allows for an effective acid neutralizing capacity that will produce less gas in the digestive system. The evolution of CO₂ gas from the neutralization reaction can naturally cause additional discomfort for obvious reasons, but

in the formulations of the present invention, the carbonate level can be reduced with a corresponding increase in the amount of calcium phosphate and calcium citrate so as to provide alternative dose forms for those individuals who are more sensitive to this development. The following Table 1 discloses three tripartite antacid formulations comprising calcium carbonate, calcium citrate, and calcium phosphate. Also disclosed are the relative percent ANC contributions and the weight in milligrams of each component in a standard antacid tablet with a total ANC of 7.5.

TABLE 1			
Acid Neutralization Capacity Percent Contribution cal. carb./cal. cit./cal. phos	Total Calcium Carbonate	Total Calcium Citrate	Total Calcium Phosphate
a) 37.5/25.0/37.5	140.0 mg.	290.0 mg	210.0 mg.
b) 25.0/25.0/50	95.0 mg.	290.0 mg.	280.0 mg.
c) 50.0/25.0/25.0	190.0 mg.	290.0 mg.	140.0 mg.

Formulation b for example, will result in the least amount of gas production since the least amount of calcium carbonate is used in terms of an acid neutralizing component.

Table 2 discloses three tripartite antacid formulations comprising calcium carbonate, calcium citrate, and magnesium citrate. Also disclosed are the relative percent ANC contributions and the weight in milligrams of each component in a standard antacid tablet with a total ANC of 10.9.

TABLE 2			
Acid Neutralization Capacity Percent Contribution cal. carb./cal. phos./mag. cit.	Total Calcium Carbonate	Total Calcium Phosphate	Total Magnesium Citrate
a) 67.9/22.9/9.2	368.4 mg.	182.0 mg	284.1 mg.
b) 45.4/45.4/9.3	249.5 mg.	369.6 mg.	287.8 mg.

Formulation b for example, will result in the least amount of gas production since the least amount of calcium carbonate is used in terms of an acid neutralizing component.

5 Along with the actives set forth above, the antacid formulations of the present invention will include a number of carrier materials, and fillers and other minor excipients normally found in most solid and liquid dosage antacid compositions. Optionally, another active such as simethicone may be added to reduce any discomfort resulting from the formation of gas that may
10 accompany the other digestive disorders and is incorporated in amounts well known in the art. Inactive ingredients, for example, may include a bulking agent such as starch, and starch derivatives, cellulose and cellulose derivatives, corn syrup, sugars, sugar alcohols and the like, lubricants such as magnesium stearate and mineral oil, tableting agents such as polyethylene glycol and titanium dioxide, silica, assorted F.D. & C. dyes,
15 flavors, high intensity sweeteners and the like. The exact types and amounts of these ingredients are well known and can be readily determined by one skilled in the art.

The antacid formulations of the present invention were effective in providing upfront and long lasting relief of stomach heartburn, acid
20 indigestion and sour stomach through the reduction in stomach acidity to a pH of from about 3.0 to about 5.0. The effectiveness of these formulations was borne out by what is known in the art as the Modified Rosset Rice procedure or the Acid Challenge test whereby the pH of a system treated with a particular formulation is measured over time. Under this procedure,
25 twenty (20) milliequivalents (megs.) of the antacid formulation to be tested are mixed with ten (10) meg. of acid (100 mls. of 0.1M HCl). This is mixed thoroughly and the pH is monitored as an additional one (1) ml. of the 0.1M HCl is added per minute. The measured pH is recorded at regular intervals and plotted as a function of time.

30 Referring now to the drawings, Fig. 1 depicts the continuous acid challenge profiles of five (5) calcium carbonate/calcium citrate formulations over a 2 hour period. All five formulations maintained pH values in the in-vitro system from about 2.9 to about 5.1. Increasing the citrate to carbonate

ratio improves the kinetics of the buffering system, providing the optimal pH (3-5) more rapidly without compromising the duration of neutralization.

5 Referring now to Fig. 2, four formulations comprising calcium carbonate/tri-basic calcium phosphate were challenged at various weight ratio amounts. A similar increase in buffering kinetics to that discussed in Figure 1 was observed when the ratio of phosphate to carbonate was increased.

10 Fig. 3 shows the result for a tripartite formulation comprising calcium carbonate/calcium citrate/tri-basic calcium phosphate in three different ratios. Whereas the optimal pH range of 3.0 to 5.0 was fairly well established and maintained (i.e. 2.9 to 4.7) all three formula ratios provided substantially similar results.

15 Fig. 4 shows the result for a tripartite formulation comprising calcium carbonate/magnesium citrate/tri-basic calcium phosphate in three different ANC ratios. Whereas the optimal pH range of 3.0 to 5.0 was fairly well established and maintained (i.e. 3.1 to 5.2) both formula ratios provided substantially similar results.

20 Obviously, numerous variations in ANC ratios and other components may be made which will alter in a minor fashion the make-up of the antacid formulations described herein. Those described above are for illustrative purposes only, and it is acknowledged that many others are possible which are still considered to fall within the spirit and scope of the present invention as recited by the following claims.

What We Claim Is:

1. An antacid pharmaceutical composition for the immediate and long lasting relief of gastrointestinal distress comprising the active agents calcium carbonate, and a second buffering agent, inactive carrier material and excipients.

2. The antacid composition of claim 1 wherein said second buffering agent is selected from the group consisting of calcium citrate, calcium phosphate and magnesium citrate.

3. The antacid composition of claim 2 wherein the active ingredients solely comprise calcium carbonate and calcium citrate in amounts that contribute to the total acid neutralization capacity of the composition in ratios of from about 20:80 to about 80:20, respectively.

4. The antacid of claim 3 wherein the active agents solely comprise calcium carbonate and calcium phosphate in amounts that are effective in contributing to the total acid neutralization capacity of the composition in ratios of from about 20:80 to about 80:20, respectively.

5. The antacid composition of claim 4 further comprising calcium citrate.

6. The antacid composition of claim 4 further comprising magnesium citrate.

7. The antacid composition of claim 5 wherein said calcium carbonate, calcium citrate and calcium phosphate are incorporated into the compositions in amounts that are effective in contributing to the total acid neutralization capacity in ratios of from about 60:20:20 to about 10:35:45, respectively.

8. The antacid composition of claim 7 wherein said calcium carbonate, calcium citrate and calcium phosphate are incorporated into the composition in amounts that are effective in contributing to the total acid neutralization capacity of the composition in a ratio of about 30:30:40, respectively.

5 9. The antacid composition of claim 6 wherein said calcium carbonate, calcium phosphate and magnesium citrate are incorporated into the composition in amounts that are effective in contributing to the total acid neutralization capacity of the composition in ratios of from about 80:15:5 to about 20:50:30, respectively.

10 10. The antacid composition of claim 9 wherein said calcium carbonate, calcium phosphate and magnesium citrate are incorporated into the composition in amounts that are effective in contributing to the total acid neutralization capacity of the composition in a ratio of about 45:45:10.

11. The antacid composition of claim 7 or claim 9 wherein said carrier materials are selected from the group consisting of cellulose, cellulose derivatives, starches, sugars, sugar alcohols, silicates, corn syrup, silica, mineral oil, polyethylene glycol, talc and mixtures thereof.

15 12. The antacid composition of claim 11 wherein said excipients are selected from the group consisting of tableting agents, lubricating agents, simethicone, artificial high intensity sweeteners, F.D. & C. food colors, flavors and mixtures thereof.

20 13. The antacid composition of claim 12 prepared as a chewable tablet dosage form.

14. The antacid composition of claim 13 prepared as a liquid dosage form.

25 15. A low sodium antacid and dietary calcium supplement comprising calcium carbonate, calcium citrate, calcium phosphate, carrier materials excipients and fillers.

30 16. The antacid composition of claim 15 wherein said calcium carbonate, calcium citrate and calcium phosphate are incorporated into the composition in amounts that are effective in contributing to the total acid neutralization capacity in ratios of from about 60:20:20 to about 10:35:45, respectively.

17. The antacid composition of claim 16 wherein said calcium carbonate, calcium citrate and calcium phosphate are incorporated into the composition in amounts that are effective in contributing to the total acid neutralization capacity of the composition in a ratio of about 30:30:40, respectively.

18. A low sodium antacid and dietary calcium supplement comprising calcium carbonate, calcium phosphate, magnesium citrate, carrier materials, excipients and fillers.

19. The antacid composition of claim 18 wherein said calcium carbonate, calcium phosphate and magnesium citrate are incorporated into the composition in amounts that are effective in contributing to the total acid neutralization capacity of the composition in a ratio of about 80:15:5 to about 20:50:30, respectively.

20. The antacid composition of claim 18 wherein said calcium carbonate, calcium phosphate and magnesium citrate are incorporated into the composition in amounts that are effective in contributing to the total acid neutralization capacity of the composition in a ratio of about 45:45:10.

21. The antacid composition of claim 16 or claim 18 wherein said carrier materials are selected from the group consisting of cellulose, cellulose derivatives, starches, sugars, sugar alcohols, silicates, polyethyleneglycol, talc and mixtures thereof.

22. The antacid composition of claim 21 wherein said excipients are selected from the group consisting of tableting agents, lubricating agents, artificial high intensity sweeteners, F.D. & C. food colors, flavors and mixtures thereof.

23. The antacid composition of claim 22 prepared as a chewable tablet dosage form.

24. The antacid composition of claim 22 prepared as a liquid dosage form.

FIG-1




FIG-2




FIG-3





FIG--4



—△— = CC/CP/Mg 67.9/22.9/9.2
—□— = CC/CP/Mg 45.4/45.4/9.3

INTERNATIONAL SEARCH REPORT

Intern. AI Application No
PCT/US 94/11548

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K33/42 A61K33/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,3 384 546 (MILES LABORATORIES, INC.) 21 May 1968 see column 8; example 6 ---	1
X	GB,A,1 056 212 (BRUNO PUETZER, LEONARD MACLES AND MARTIN PERL) 8 February 1965 see column 1, line 19 - line 39 ---	1
X	DE,A,19 15 798 (SMITH KLINE & FRENCH LABORATORIES) 6 November 1969 see page 7, paragraph 2; claim 1 ---	1,2
X	GB,A,922 038 (LEWIS HOWE CO.) 27 April 1963 see examples -----	1

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is considered with one or more other such documents, such combination being obvious to a person skilled in the art
- *A* document member of the same patent family

Date of the actual completion of the international search

26 January 1995

Date of sending of the international search report

31.01.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-3040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Leherte, C

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 94/11548

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-3384546	21-05-68	GB-A- 1187631	08-04-70
GB-A-1056212		NONE	
DE-A-1915798	06-11-69	BE-A- 731060	06-10-69
		FR-A,B 2005599	12-12-69
		GB-A- 1200157	29-07-70
		LU-A- 58367	09-11-70
		NL-A- 6905135	07-10-69
		US-A- 3621094	16-11-71
GB-A-922038		NONE	

PATENTS SUMMARY

07/31/98

Page 1

Country : Patent Cooperation Treaty (PCT)

Patent #: 95-010290 A

Index#: 5652

Inventor: Constantine Georgiades et al.

Issue Date: 04/20/95

Assignee: Warner-Lambert Company

Date of Application: 10/13/93

Title:

ANTACID PHARMACEUTICAL COMPOSITION

Desc.:

An antacid pharmaceutical composition for the immediate and long lasting relief of upper gastrointestinal distress is claimed. The composition may be in a chewable tablet or liquid dosage form and contains calcium carbonate and a second buffering agent as active ingredients with inactive carrier material and excipients. The second buffering agent is selected from calcium citrate, calcium phosphate and magnesium citrate. The composition is low in sodium and aluminum-free and has good taste and mouthfeel.

Key Words:

50 LOW INTENSITY SWEETENERS

250 FOOD COLORS

400 FLAVORS/FRAGRANCES

460 Acids/Buffers/pH

461 Salt, Ions, Metals, Minerals

462 Cellulose, Chitin & Derivatives

463 Starch

467 Pharmaceutical Agents

491 Chemicals

525 Chemical Synthesis/Preparation

555 Fast or Slow Release/Long Lasting

559 Solubility

563 Mouthfeel

574 Health Benefit

579 Flavor Improvement

712 Warner-Lambert/American Chicle

810 Patent Cooperation Treaty (PCT)